TY - JOUR AU - Sellares, J. AU - Freitas, D. G. AU - Mengel, M. AU - Reeve, J. AU - Einecke, G. AU - Sis, B. PY - 2012 DA - 2012// TI - Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence JO - Am J Transplant VL - 12 UR - https://doi.org/10.1111/j.1600-6143.2011.03840.x DO - 10.1111/j.1600-6143.2011.03840.x ID - Sellares2012 ER - TY - JOUR AU - Loupy, A. AU - Jordan, S. C. PY - 2013 DA - 2013// TI - Transplantation: Donor-specific HLA antibodies and renal allograft failure JO - Nat Rev Nephrol. VL - 9 UR - https://doi.org/10.1038/nrneph.2013.18 DO - 10.1038/nrneph.2013.18 ID - Loupy2013 ER - TY - JOUR AU - Djamali, A. AU - Kaufman, D. B. AU - Ellis, T. M. AU - Zhong, W. AU - Matas, A. AU - Samaniego, M. PY - 2014 DA - 2014// TI - Diagnosis and management of antibody-mediated rejection: current status and novel approaches JO - Am J Transplant VL - 14 UR - https://doi.org/10.1111/ajt.12589 DO - 10.1111/ajt.12589 ID - Djamali2014 ER - TY - JOUR AU - Haas, M. AU - Loupy, A. AU - Lefaucheur, C. AU - Roufosse, C. AU - Glotz, D. AU - Seron, D. PY - 2018 DA - 2018// TI - The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials JO - Am J Transplant VL - 18 UR - https://doi.org/10.1111/ajt.14625 DO - 10.1111/ajt.14625 ID - Haas2018 ER - TY - JOUR AU - Halloran, P. F. AU - Famulski, K. S. AU - Reeve, J. PY - 2016 DA - 2016// TI - Molecular assessment of disease states in kidney transplant biopsy samples JO - Nat Rev Nephrol VL - 12 UR - https://doi.org/10.1038/nrneph.2016.85 DO - 10.1038/nrneph.2016.85 ID - Halloran2016 ER - TY - JOUR AU - Theruvath, T. P. AU - Saidman, S. L. AU - Mauiyyedi, S. AU - Delmonico, F. L. AU - Williams, W. W. AU - Tolkoff-Rubin, N. PY - 2001 DA - 2001// TI - Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection JO - Transplantation VL - 72 UR - https://doi.org/10.1097/00007890-200107150-00016 DO - 10.1097/00007890-200107150-00016 ID - Theruvath2001 ER - TY - JOUR AU - Lederer, S. R. AU - Friedrich, N. AU - Banas, B. AU - Welser, G. AU - Albert, E. D. AU - Sitter, T. PY - 2005 DA - 2005// TI - Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation JO - Clin Transpl VL - 19 UR - https://doi.org/10.1111/j.1399-0012.2005.00261.x DO - 10.1111/j.1399-0012.2005.00261.x ID - Lederer2005 ER - TY - JOUR AU - Schwarz, C. AU - Regele, H. AU - Huttary, N. AU - Wahrmann, M. AU - Exner, M. AU - Nagy-Bojarsky, K. PY - 2006 DA - 2006// TI - Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy JO - Wien Klin Wochenschr VL - 118 UR - https://doi.org/10.1007/s00508-006-0531-3 DO - 10.1007/s00508-006-0531-3 ID - Schwarz2006 ER - TY - JOUR AU - Fehr, T. AU - Rusi, B. AU - Fischer, A. AU - Hopfer, H. AU - Wüthrich, R. P. AU - Gaspert, A. PY - 2009 DA - 2009// TI - Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection JO - Transplantation VL - 87 UR - https://doi.org/10.1097/TP.0b013e3181a6bac5 DO - 10.1097/TP.0b013e3181a6bac5 ID - Fehr2009 ER - TY - JOUR AU - Billing, H. AU - Rieger, S. AU - Süsal, C. AU - Waldherr, R. AU - Opelz, G. AU - Wühl, E. PY - 2012 DA - 2012// TI - IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up JO - Transpl Int VL - 25 UR - https://doi.org/10.1111/j.1432-2277.2012.01544.x DO - 10.1111/j.1432-2277.2012.01544.x ID - Billing2012 ER - TY - JOUR AU - Cooper, J. E. AU - Gralla, J. AU - Klem, P. AU - Chan, L. AU - Wiseman, A. C. PY - 2014 DA - 2014// TI - High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction JO - Transplantation VL - 97 UR - https://doi.org/10.1097/01.TP.0000443226.74584.03 DO - 10.1097/01.TP.0000443226.74584.03 ID - Cooper2014 ER - TY - JOUR AU - Bachelet, T. AU - Nodimar, C. AU - Taupin, J. L. AU - Lepreux, S. AU - Moreau, K. AU - Morel, D. PY - 2015 DA - 2015// TI - Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study JO - Clin Transpl VL - 29 UR - https://doi.org/10.1111/ctr.12535 DO - 10.1111/ctr.12535 ID - Bachelet2015 ER - TY - JOUR AU - Walsh, R. C. AU - Alloway, R. R. AU - Girnita, A. L. AU - Woodle, E. S. PY - 2012 DA - 2012// TI - Proteasome inhibitor-based therapy for antibody-mediated rejection JO - Kidney Int VL - 81 UR - https://doi.org/10.1038/ki.2011.502 DO - 10.1038/ki.2011.502 ID - Walsh2012 ER - TY - JOUR AU - Eskandary, F. AU - Jilma, B. AU - Mühlbacher, J. AU - Wahrmann, M. AU - Regele, H. AU - Kozakowski, N. PY - 2017 DA - 2017// TI - Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial JO - Am J Transplant VL - 18 UR - https://doi.org/10.1111/ajt.14528 DO - 10.1111/ajt.14528 ID - Eskandary2017 ER - TY - JOUR AU - Cornell, L. D. AU - Schinstock, C. A. AU - Gandhi, M. J. AU - Kremers, W. K. AU - Stegall, M. D. PY - 2015 DA - 2015// TI - Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year JO - Am J Transplant VL - 15 UR - https://doi.org/10.1111/ajt.13168 DO - 10.1111/ajt.13168 ID - Cornell2015 ER - TY - JOUR AU - Moreso, F. AU - Crespo, M. AU - Ruiz, J. C. AU - Torres, A. AU - Gutierrez-Dalmau, A. AU - Osuna, A. PY - 2018 DA - 2018// TI - Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial JO - Am J Transplant VL - 18 UR - https://doi.org/10.1111/ajt.14520 DO - 10.1111/ajt.14520 ID - Moreso2018 ER - TY - JOUR AU - Eskandary, F. AU - Regele, H. AU - Baumann, L. AU - Bong, G. AU - Kozakowski, N. AU - Wahrmann, M. PY - 2018 DA - 2018// TI - A randomized trial of bortezomib in late antibody-mediated rejection (BORTEJECT) JO - J Am Soc Nephrol VL - 29 UR - https://doi.org/10.1681/ASN.2017070818 DO - 10.1681/ASN.2017070818 ID - Eskandary2018 ER - TY - JOUR AU - Jordan, S. C. AU - Choi, J. AU - Kim, I. AU - Wu, G. AU - Toyoda, M. AU - Shin, B. PY - 2017 DA - 2017// TI - Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade JO - Transplantation VL - 101 UR - https://doi.org/10.1097/TP.0000000000001452 DO - 10.1097/TP.0000000000001452 ID - Jordan2017 ER - TY - JOUR AU - Smolen, J. S. AU - Beaulieu, A. AU - Rubbert-Roth, A. AU - Ramos-Remus, C. AU - Rovensky, J. AU - Alecock, E. PY - 2008 DA - 2008// TI - Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial JO - Lancet VL - 371 UR - https://doi.org/10.1016/S0140-6736(08)60453-5 DO - 10.1016/S0140-6736(08)60453-5 ID - Smolen2008 ER - TY - JOUR AU - Weinblatt, M. E. AU - Mease, P. AU - Mysler, E. AU - Takeuchi, T. AU - Drescher, E. AU - Berman, A. PY - 2015 DA - 2015// TI - The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study JO - Arthritis Rheumatol VL - 67 UR - https://doi.org/10.1002/art.39249 DO - 10.1002/art.39249 ID - Weinblatt2015 ER - TY - JOUR AU - Aletaha, D. AU - Bingham, C. O. AU - Tanaka, Y. AU - Agarwal, P. AU - Kurrasch, R. AU - Tak, P. P. PY - 2017 DA - 2017// TI - Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(17)30401-4 DO - 10.1016/S0140-6736(17)30401-4 ID - Aletaha2017 ER - TY - JOUR AU - Choi, J. AU - Aubert, O. AU - Vo, A. AU - Loupy, A. AU - Haas, M. AU - Puliyanda, D. PY - 2017 DA - 2017// TI - Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients JO - Am J Transplant VL - 17 UR - https://doi.org/10.1111/ajt.14228 DO - 10.1111/ajt.14228 ID - Choi2017 ER - TY - JOUR AU - Bayliss, T. J. AU - Smith, J. T. AU - Schuster, M. AU - Dragnev, K. H. AU - Rigas, J. R. PY - 2011 DA - 2011// TI - A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer JO - Expert Opin Biol Ther VL - 11 UR - https://doi.org/10.1517/14712598.2011.627850 DO - 10.1517/14712598.2011.627850 ID - Bayliss2011 ER - TY - JOUR AU - Mease, P. AU - Strand, V. AU - Shalamberidze, L. AU - Dimic, A. AU - Raskina, T. AU - Xu, L. A. PY - 2012 DA - 2012// TI - A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate JO - Ann Rheum Dis VL - 71 UR - https://doi.org/10.1136/annrheumdis-2011-200704 DO - 10.1136/annrheumdis-2011-200704 ID - Mease2012 ER - TY - JOUR AU - Mease, P. J. AU - Gottlieb, A. B. AU - Berman, A. AU - Drescher, E. AU - Xing, J. AU - Wong, R. PY - 2016 DA - 2016// TI - The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis JO - Arthritis Rheumatol VL - 68 UR - https://doi.org/10.1002/art.39700 DO - 10.1002/art.39700 ID - Mease2016 ER - TY - JOUR AU - Rossi, J. F. AU - Lu, Z. Y. AU - Jourdan, M. AU - Klein, B. PY - 2015 DA - 2015// TI - Interleukin-6 as a therapeutic target JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2291 DO - 10.1158/1078-0432.CCR-14-2291 ID - Rossi2015 ER - TY - JOUR AU - Schoergenhofer, C. AU - Hobl, E. L. AU - Schellongowski, P. AU - Heinz, G. AU - Speidl, W. S. AU - Siller-Matula, J. M. PY - 2018 DA - 2018// TI - Clopidogrel in critically ill patients JO - Clin Pharmacol Ther VL - 103 UR - https://doi.org/10.1002/cpt.878 DO - 10.1002/cpt.878 ID - Schoergenhofer2018 ER - TY - JOUR AU - Reeve, J. AU - Böhmig, G. A. AU - Eskandary, F. AU - Einecke, G. AU - Lefaucheur, C. AU - Loupy, A. PY - 2017 DA - 2017// TI - Precision molecular phenotyping of kidney transplant biopsies using archetypal analysis JO - JCI Insight VL - 2 UR - https://doi.org/10.1172/jci.insight.94197 DO - 10.1172/jci.insight.94197 ID - Reeve2017 ER - TY - JOUR AU - Streitz, M. AU - Miloud, T. AU - Kapinsky, M. AU - Reed, M. R. AU - Magari, R. AU - Geissler, E. K. PY - 2013 DA - 2013// TI - Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study JO - Transplant Res VL - 2 UR - https://doi.org/10.1186/2047-1440-2-17 DO - 10.1186/2047-1440-2-17 ID - Streitz2013 ER - TY - JOUR AU - Schiemann, M. AU - Puchhammer-Stockl, E. AU - Eskandary, F. AU - Kohlbeck, P. AU - Rasoul-Rockenschaub, S. AU - Heilos, A. PY - 2017 DA - 2017// TI - Torque Teno virus load-inverse association with antibody-mediated rejection after kidney transplantation JO - Transplantation VL - 101 UR - https://doi.org/10.1097/TP.0000000000001455 DO - 10.1097/TP.0000000000001455 ID - Schiemann2017 ER - TY - JOUR AU - Kulkarni, S. AU - Kirkiles-Smith, N. C. AU - Deng, Y. H. AU - Formica, R. N. AU - Moeckel, G. AU - Broecker, V. PY - 2017 DA - 2017// TI - Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial JO - Am J Transplant VL - 17 UR - https://doi.org/10.1111/ajt.14001 DO - 10.1111/ajt.14001 ID - Kulkarni2017 ER - TY - JOUR AU - Vlaminck, I. AU - Khush, K. K. AU - Strehl, C. AU - Kohli, B. AU - Luikart, H. AU - Neff, N. F. PY - 2013 DA - 2013// TI - Temporal response of the human virome to immunosuppression and antiviral therapy JO - Cell VL - 155 UR - https://doi.org/10.1016/j.cell.2013.10.034 DO - 10.1016/j.cell.2013.10.034 ID - Vlaminck2013 ER - TY - JOUR AU - Monemi, S. AU - Berber, E. AU - Sarsour, K. AU - Wang, J. AU - Lampl, K. AU - Bharucha, K. PY - 2016 DA - 2016// TI - Incidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources JO - Rheumatol Ther VL - 3 UR - https://doi.org/10.1007/s40744-016-0037-z DO - 10.1007/s40744-016-0037-z ID - Monemi2016 ER - TY - JOUR AU - Shah, R. R. AU - Smith, R. L. PY - 2015 DA - 2015// TI - Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine JO - Drug Metab Dispos VL - 43 UR - https://doi.org/10.1124/dmd.114.061093 DO - 10.1124/dmd.114.061093 ID - Shah2015 ER - TY - JOUR AU - Wiebe, C. AU - Nevins, T. E. AU - Robiner, W. N. AU - Thomas, W. AU - Matas, A. J. AU - Nickerson, P. W. PY - 2015 DA - 2015// TI - The synergistic effect of Class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival JO - Am J Transplant VL - 15 UR - https://doi.org/10.1111/ajt.13341 DO - 10.1111/ajt.13341 ID - Wiebe2015 ER - TY - JOUR AU - Wiebe, C. AU - Rush, D. N. AU - Nevins, T. E. AU - Birk, P. E. AU - Blydt-Hansen, T. AU - Gibson, I. W. PY - 2017 DA - 2017// TI - Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development JO - J Am Soc Nephrol VL - 28 UR - https://doi.org/10.1681/ASN.2017030287 DO - 10.1681/ASN.2017030287 ID - Wiebe2017 ER - TY - JOUR AU - Coresh, J. AU - Turin, T. C. AU - Matsushita, K. AU - Sang, Y. AU - Ballew, S. H. AU - Appel, L. J. PY - 2014 DA - 2014// TI - Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality JO - JAMA VL - 311 UR - https://doi.org/10.1001/jama.2014.6634 DO - 10.1001/jama.2014.6634 ID - Coresh2014 ER - TY - JOUR AU - Thompson, A. AU - Lawrence, J. AU - Stockbridge, N. PY - 2014 DA - 2014// TI - GFR decline as an end point in trials of CKD: a viewpoint from the FDA JO - Am J Kidney Dis VL - 64 UR - https://doi.org/10.1053/j.ajkd.2014.09.006 DO - 10.1053/j.ajkd.2014.09.006 ID - Thompson2014 ER -